|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: APBB3 |
Gene summary for APBB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | APBB3 | Gene ID | 10307 |
| Gene name | amyloid beta precursor protein binding family B member 3 | |
| Gene Alias | FE65L2 | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O95704 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10307 | APBB3 | HCC1_Meng | Human | Liver | HCC | 5.15e-03 | -1.12e-05 | 0.0246 |
| 10307 | APBB3 | HCC1 | Human | Liver | HCC | 1.84e-05 | 3.43e+00 | 0.5336 |
| 10307 | APBB3 | HCC2 | Human | Liver | HCC | 1.69e-03 | 3.37e+00 | 0.5341 |
| 10307 | APBB3 | S014 | Human | Liver | HCC | 3.70e-02 | 1.87e-01 | 0.2254 |
| 10307 | APBB3 | S016 | Human | Liver | HCC | 1.31e-06 | 2.43e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
| GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
| GO:003559212 | Liver | HCC | establishment of protein localization to extracellular region | 176/7958 | 360/18723 | 7.96e-03 | 3.15e-02 | 176 |
| GO:000930612 | Liver | HCC | protein secretion | 175/7958 | 359/18723 | 9.32e-03 | 3.57e-02 | 175 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| APBB3 | SNV | Missense_Mutation | rs761240609 | c.59N>C | p.Trp20Ser | p.W20S | O95704 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CC-A7IE-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| APBB3 | SNV | Missense_Mutation | novel | c.443A>G | p.Gln148Arg | p.Q148R | O95704 | protein_coding | tolerated(1) | probably_damaging(0.997) | TCGA-DD-AAE7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| APBB3 | SNV | Missense_Mutation | c.287N>C | p.Arg96Pro | p.R96P | O95704 | protein_coding | tolerated(0.21) | benign(0.419) | TCGA-50-6592-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| APBB3 | SNV | Missense_Mutation | c.744N>A | p.Ser248Arg | p.S248R | O95704 | protein_coding | deleterious(0) | benign(0.441) | TCGA-97-7554-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD | |
| APBB3 | SNV | Missense_Mutation | novel | c.560A>G | p.His187Arg | p.H187R | O95704 | protein_coding | tolerated(0.95) | benign(0.007) | TCGA-85-8481-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| APBB3 | SNV | Missense_Mutation | c.1421G>T | p.Arg474Leu | p.R474L | O95704 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-CV-7252-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| APBB3 | SNV | Missense_Mutation | c.1112T>G | p.Phe371Cys | p.F371C | O95704 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G9-6343-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | |
| APBB3 | SNV | Missense_Mutation | rs138766975 | c.1316N>A | p.Arg439His | p.R439H | O95704 | protein_coding | tolerated(0.52) | possibly_damaging(0.825) | TCGA-G9-6354-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
| APBB3 | SNV | Missense_Mutation | novel | c.400N>A | p.Leu134Met | p.L134M | O95704 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| APBB3 | SNV | Missense_Mutation | c.533N>T | p.Ala178Val | p.A178V | O95704 | protein_coding | deleterious(0.04) | benign(0.234) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |